- About us
- Clinical trials
- News & Publications
SOTIO launches first clinical trial of a new treatment for lung cancer, a disease which threatens more people globally than other cancers.
SOTIO, a biotechnology company owned by the PPF Group, today announced that the first patient has been enrolled into its recently launched international study in lung cancer a Phase I/II clinical trial using its Dendritic Cell Vaccine (DCVAC/LuCa), an active cellular immunotherapy treatment. Lung cancer has become the most common newly diagnosed tumour disease globally and is also the most frequent cause of death among patients suffering from cancer.
SOTIO Initiates US Part of VIABLE, a Global Phase III Clinical Trial for Prostate Cancer Immunotherapy Treatment Using DCVAC/PCa
SOTIO, a biotechnology company owned by the PPF Group, today announced that the first US patient has been enrolled in its VIABLE study, the global Phase III clinical trial for DCVAC/PCa, an active cellular immunotherapy treatment for prostate cancer patients. Initial patients were also recently enrolled into the study in Italy, UK, the Netherlands and Slovakia.
SOTIO exhibits at ESMO 2014
SOTIO, the biotechnology company owned by PPF Group, is presenting its clinical research program at the European Society for Medical Oncology’s 2014 Congress in Madrid (ESMO 2014). SOTIO’s exhibit can be found at booth no.107 in ESMO Exhibition Hall no. 8. Over the course of the ESMO Congress, SOTIO’s representatives will meet with important key opinion leaders (KOLs), researchers participating in company clinical trials and other medical and clinical experts.